Lynch Regenerative Medicine, LLC ("LRM" or the "Company"), a commercial stage biotech company advancing regenerative medicine through innovative therapies and aesthetic solutions, has announced the ...

Patients with small melanoma in situ (MIS) on low-risk body sites that was managed with 5-mm margins had a local recurrence rate of 0.9%, results from a retrospective case series from a single ...

The randomised, double-blind, controlled trial has enrolled a total of 34 patients.

Stage 2 melanoma involves a significant tumor without lymph node or distant organ spread, determined by tumor thickness and ulceration. Treatment focuses on curative surgical excision, with adjuvant ...

In a retrospective cohort of patients with melanoma in situ (MIS) with non-lentigo maligna/non-acral lentiginous (non-LM/non-ALM) subtypes, no local recurrences, metastases, or melanoma-specific ...

Mitotic rate ≥1/mm² and residual tumor presence are linked to higher relapse risk in cutaneous melanoma patients post-excision. Lymphovascular invasion significantly correlates with worse relapse-free ...

A phase 1/2 study of vusolimogene oderparepvec (RP1) in primary melanoma (mel) to reduce the risk of sentinel lymph node (SLN) metastasis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Surgery is usually the main treatment for most types and stages of melanoma. If your tumor is in an early stage and removed using a melanoma surgical treatment, you may not need any other treatment.